In Canada, between 3,000 and 4,000 people are living with amyotrophic lateral sclerosis (ALS), a disease that remains ...
Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic MEK inhibitor, today announced that ...
In conjunction with MLB’s annual Lou Gehrig Day, the Cincinnati Reds invited those battling Amyotrophic Lateral Sclerosis ...
Our Phase 2 design reflects both the translational science and the realities of ALS by integrating validated biomarkers such as neurofilament light chain alongside clinically meaningful endpoints,” ...
The National Academies of Sciences, Engineering, and Medicine recently released a congressionally mandated report on how to make amyotrophic lateral sclerosis — a brutal, always fatal condition — a ...
In Canada, between 3,000 and 4,000 people are living with amyotrophic lateral sclerosis (ALS), a disease that remains ...
The Daily World on MSN
Cosmopolis Elementary students plant seeds of hope with ALS walk-a-thon
Cosmopolis Elementary School recently raised more than $5,000 for the ALS Association through a student-led fundraising ...
Chicago, June 23, 2025 (GLOBE NEWSWIRE) -- The global amyotrophic lateral sclerosis treatment market is projected to grow from USD 724.5 million in 2024 to USD 1,234.5 million by 2033, reflecting a ...
Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results